Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Dyne Therapeutics has raised $375.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Dyne Therapeutics's investors include Franklin Templeton, RA Capital Management, Wellington Management, Vida Ventures, Forbion Capital Partners.
Dyne Therapeutics is headquartered in Cambridge, United States.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Dyne Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dyne Therapeutics — Funding & Investors." VCBacked, July 21, 2026, https://www.vcbacked.co/company/dyne-therapeutics. Accessed September 2, 2026.
VCBacked. (2026). Dyne Therapeutics — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/dyne-therapeutics
{{cite web |title=Dyne Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dyne-therapeutics |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated